Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F21%3A00559315" target="_blank" >RIV/61388971:_____/21:00559315 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/21:73608612
Result on the web
<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259643" target="_blank" >https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259643</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1371/journal.pone.0259643" target="_blank" >10.1371/journal.pone.0259643</a>
Alternative languages
Result language
angličtina
Original language name
Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression
Original language description
Microbiome is now considered as a significant metabolic organ with an immense potential to influence overall human health. A number of diseases that are associated with pharmacotherapy interventions was linked with altered gut microbiota. Moreover, it has been reported earlier that gut microbiome modulates the fate of more than 30 commonly used drugs and, vice versa, drugs have been shown to affect the composition of the gut microbiome. The molecular mechanisms of this mutual relationship, however, remain mostly elusive. Recent studies indicate an indirect effect of the gut microbiome through its metabolites on the expression of biotransformation enzymes in the liver. The aim of this study was to analyse the effect of gut microbiome on the fate of metronidazole in the mice through modulation of system of drug metabolizing enzymes, namely by alteration of the expression and activity of selected cytochromes P450 (CYPs). To assess the influence of gut microbiome, germ-free mice (GF) in comparison to control specific-pathogen-free (SPF) mice were used. First, it has been found that the absence of microbiota significantly affected plasma concentration of metronidazole, resulting in higher levels (by 30%) of the parent drug in murine plasma of GF mice. Further, the significant interaction between presence/absence of the gut microbiome and effect of metronidazole application, which together influence mRNA expression of CAR, PPAR alpha, Cyp2b10 and Cyp2c38 was determined. Administration of metronidazole itself influenced significantly mRNA expression of Cyp1a2, Cyp2b10, Cyp2c38 and Cyp2d22. Finally, GF mice have shown lower level of enzyme activity of CYP2A and CYP3A than their SPF counterparts. The results hence have shown that, beside direct bacterial metabolism, different expression and enzyme activity of hepatic CYPs in the presence/absence of gut microbiota may be responsible for the altered metronidazole metabolism.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30502 - Other medical science
Result continuities
Project
<a href="/en/project/GA19-08294S" target="_blank" >GA19-08294S: Gut microbiota and host intestinal inflammation. Mechanism of bacterial and butyrate action in alleviating the consequences of dysbiosis</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
PLoS ONE
ISSN
1932-6203
e-ISSN
1932-6203
Volume of the periodical
16
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
16
Pages from-to
e0259643
UT code for WoS article
000754499700021
EID of the result in the Scopus database
2-s2.0-85118825179